We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
造血幹細胞移植は，化学療法抵抗性の造血器悪性腫瘍（白血病，骨髄腫，悪性リンパ腫など）や，幹細胞自体のダメージによる造血障害（再生不良性貧血など）の完治を目指して行う治療である．
No takes yet. Share an insight, caveat, or question.
Shinya Mizumura (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: